↓ Skip to main content

Dove Medical Press

Article Metrics

Cost–utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, July 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
27 Mendeley
Title
Cost–utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model
Published in
ClinicoEconomics and Outcomes Research: CEOR, July 2013
DOI 10.2147/ceor.s42170
Pubmed ID
Authors

Lee, Bong Yang, Hong, Lee, Kim, Jae Weon Kim, Kim, Kim, Kang

Abstract

We performed a cost-utility analysis to assess the cost-effectiveness of a chemotherapy sequence including a combination of polyethylene glycolated liposomal doxorubicin (PLD)/carboplatin versus paclitaxel/carboplatin as a second-line treatment in women with platinum-sensitive ovarian cancer.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 19%
Researcher 4 15%
Student > Master 3 11%
Student > Bachelor 2 7%
Student > Doctoral Student 2 7%
Other 5 19%
Unknown 6 22%
Readers by discipline Count As %
Medicine and Dentistry 8 30%
Economics, Econometrics and Finance 3 11%
Social Sciences 2 7%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Agricultural and Biological Sciences 1 4%
Other 3 11%
Unknown 8 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2013.
All research outputs
#3,135,598
of 4,505,617 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#131
of 156 outputs
Outputs of similar age
#70,890
of 101,293 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#15
of 15 outputs
Altmetric has tracked 4,505,617 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 156 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 101,293 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.